TD Cowen analyst Yaron Werber has maintained their bullish stance on STOK stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yaron Werber has given his Buy rating due to a combination of factors that highlight Stoke Therapeutics’ promising outlook. The ongoing Phase 3 EMPEROR trial is progressing well, with over 130 patients pre-screened and multiple active sites across the US, UK, and Japan. The trial is well-powered to assess seizure reduction and improvements in Vineland-3 scores, with data expected in the second half of 2027. Additionally, the recent three-year open-label extension data has shown continued efficacy in reducing seizure frequency and improving Vineland-3 scores, with no new safety concerns emerging.
Another positive development is the initiation of the Phase 1 SAD trial for STK-002 in adults with ADOA in the UK and EU, addressing a significant unmet need in a currently untreatable condition. The company’s strong financial position, with $355 million in cash expected to last until mid-2028, supports its ongoing trials and potential market opportunities. These factors combined present a compelling risk-reward scenario, justifying the Buy rating.
In another report released today, Chardan Capital also reiterated a Buy rating on the stock with a $24.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STOK in relation to earlier this year.